Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Gossamer Bio Inc's Business Segments
Gossamer Bio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Reporting
Total Revenue
$ 17
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Reporting100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reporting | $ 17 | 100% |
Revenue by Product & Service Category - Q1 FY2026
- Revenue from Contracts with Collaborators100%
- PAH Research and Development Services, Performance Obligations Satisfied41.6%
- Ph-ild Research and Development Services, Performance Obligations Satisfied3.6%
- Effects of Exchange Rate0.3%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Revenue from Contracts with Collaborators | $ 17 | 100% |
| PAH Research and Development Services, Performance Obligations Satisfied | $ 7 | 41.6% |
| Ph-ild Research and Development Services, Performance Obligations Satisfied | $ 1 | 3.6% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
1 more categories available
Sign in to unlock the full Gossamer Bio Inc dataset.
Description of Gossamer Bio Inc
Gossamer Bio Inc. is a biopharmaceutical company that focuses on discovering, developing and commercializing therapeutics that address unmet needs in the treatment of various infectious, inflammatory and oncology diseases. It was founded in 2015 by Dr. Faheem Hasnain and Dr. Sheila Gujrathi, both of whom have extensive experience in the pharmaceutical industry and have previously worked together at Receptos, a biopharmaceutical company that was acquired by Celgene in 201
The company is headquartered in San Diego, California, and has a robust pipeline of candidates for various indications. Gossamer Bio has a strong focus on cutting-edge technology and market research to stay ahead of the competition. It has developed and acquired intellectual property rights in various small molecule drugs, proteins, and therapeutics.
Gossamer Bio's pipeline includes candidates that target Type 2 inflammation, COVID-19, and multiple oncology programs. Its lead product candidate, GB001, is a small molecule antagonist of the prostaglandin D2 receptor 2 (DP2) designed to treat eosinophilic asthma and chronic rhinosinusitis with nasal polyps. The company is also developing GB002, an inhaled inhibitor of IL-9, for the treatment of asthma, as well as biologic programs that target Type 2 inflammation.
In response to the COVID-19 pandemic, Gossamer Bio has developed GB004, an antibody drug designed to prevent and treat severe COVID-19 infections. It is a SARS-CoV-2-neutralizing antibody that has been shown to have potent in vitro neutralizing activity against multiple variants of the virus. The company is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of GB004 as a treatment for COVID-19.
In the oncology space, Gossamer Bio is developing GB1275, an oral CD11b agonist inhibitor that is designed to treat a wide range of solid tumors. GB1275 is currently being tested in Phase 2 clinical trials for various indications. The company is also developing GB2064, a first-in-class oral hypoxia-inducible factor (HIF) inhibitor that is designed to treat a wide range of solid tumors.
In addition to its clinical programs, Gossamer Bio has initiated preclinical research on multiple other programs, including candidates for the treatment of chronic obstructive pulmonary disease, fibrotic disorders, and various oncology programs.
Gossamer Bio has established collaborations with various academic institutions, pharmaceutical companies, and research organizations to further advance its pipeline candidates. The company has secured several rounds of funding from both institutional investors and venture capitalists and has a strong financial position to support its ongoing operations.
In summary, Gossamer Bio Inc. is a biopharmaceutical company that is focused on discovering and developing innovative therapeutics that treat a wide range of infectious, inflammatory, and oncology diseases. With a robust pipeline of candidates and a strong foundation of scientific and technological expertise, Gossamer Bio is poised to emerge as a leading player in the biopharmaceutical industry.
The company is headquartered in San Diego, California, and has a robust pipeline of candidates for various indications. Gossamer Bio has a strong focus on cutting-edge technology and market research to stay ahead of the competition. It has developed and acquired intellectual property rights in various small molecule drugs, proteins, and therapeutics.
Gossamer Bio's pipeline includes candidates that target Type 2 inflammation, COVID-19, and multiple oncology programs. Its lead product candidate, GB001, is a small molecule antagonist of the prostaglandin D2 receptor 2 (DP2) designed to treat eosinophilic asthma and chronic rhinosinusitis with nasal polyps. The company is also developing GB002, an inhaled inhibitor of IL-9, for the treatment of asthma, as well as biologic programs that target Type 2 inflammation.
In response to the COVID-19 pandemic, Gossamer Bio has developed GB004, an antibody drug designed to prevent and treat severe COVID-19 infections. It is a SARS-CoV-2-neutralizing antibody that has been shown to have potent in vitro neutralizing activity against multiple variants of the virus. The company is currently conducting Phase 2 clinical trials to evaluate the safety and efficacy of GB004 as a treatment for COVID-19.
In the oncology space, Gossamer Bio is developing GB1275, an oral CD11b agonist inhibitor that is designed to treat a wide range of solid tumors. GB1275 is currently being tested in Phase 2 clinical trials for various indications. The company is also developing GB2064, a first-in-class oral hypoxia-inducible factor (HIF) inhibitor that is designed to treat a wide range of solid tumors.
In addition to its clinical programs, Gossamer Bio has initiated preclinical research on multiple other programs, including candidates for the treatment of chronic obstructive pulmonary disease, fibrotic disorders, and various oncology programs.
Gossamer Bio has established collaborations with various academic institutions, pharmaceutical companies, and research organizations to further advance its pipeline candidates. The company has secured several rounds of funding from both institutional investors and venture capitalists and has a strong financial position to support its ongoing operations.
In summary, Gossamer Bio Inc. is a biopharmaceutical company that is focused on discovering and developing innovative therapeutics that treat a wide range of infectious, inflammatory, and oncology diseases. With a robust pipeline of candidates and a strong foundation of scientific and technological expertise, Gossamer Bio is poised to emerge as a leading player in the biopharmaceutical industry.
Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies in the fields of immunology, inflammation, and oncology. Its extensive portfolio is structured into distinct segments, each addressing critical unmet medical needs through a diverse array of products and services.
1. Segments
a) Immunology
The Immunology segment of Gossamer Bio aims to create next-generation therapeutics for various autoimmune and allergic conditions. This includes diseases such as:
- Asthma: Gossamer is focused on developing treatments that can potentially provide more effective control of asthma symptoms and prevent exacerbations.
- Inflammatory Bowel Disease (IBD): This encompasses conditions such as Crohns disease and ulcerative colitis, where the company is exploring innovative treatments to improve patient outcomes and quality of life.
- Dermatitis: Gossamers research includes therapies targeted at various forms of dermatitis, potentially alleviating symptoms and addressing underlying mechanisms of these diseases.
- Psoriasis: The company is developing therapies aimed at the root causes of psoriasis, a chronic inflammatory skin condition.
b) Inflammation
This segment is centered on addressing chronic inflammatory diseases, experiencing significant advancements with a focus on:
- Chronic Obstructive Pulmonary Disease (COPD): Gossamer is committed to developing new medications that can reduce inflammation in the lungs and enhance airflow, thereby improving patient conditions.
- Idiopathic Pulmonary Fibrosis (IPF): Gossamer’s research in this area includes finding therapies that can mitigate lung scarring and improve respiratory function.
- Kidney Diseases: The company is exploring innovative approaches to treating various chronic kidney conditions that are driven by inflammatory processes.
c) Oncology
In the Oncology segment, Gossamer Bio is dedicated to innovating therapies for a variety of cancers:
- Hematologic Malignancies: This includes blood cancers such as leukemias and lymphomas, for which Gossamer is targeting distinct pathways to improve treatment outcomes.
- Solid Tumors: The company works on therapies designed to combat solid tumors, which can encompass various forms of cancer affecting organs and tissues throughout the body.
- Rare Cancers: Gossamer is also focusing on therapies for rare cancers, where options are often limited and there exists a critical need for new treatment modalities.
Products
Gossamer Bio’s product portfolio features several promising candidates that are at various stages of development:
a) GB001
GB001 is a selective inhibitor of the prostaglandin D2 receptor 2 (DP2). It is primarily being developed for treating asthma and other allergic diseases, aiming to block inflammatory pathways involved in these conditions.
b) GB002
GB002 is a small molecule inhibitor of the HER3 receptor, which plays a crucial role in cancer cell proliferation. This product is being developed to target various types of cancer, particularly those resistant to other therapies.
c) GB004
GB004 is a monoclonal antibody designed to target the IL-17 pathway, which is integral to many inflammatory diseases. It holds potential for treating conditions like psoriasis, psoriatic arthritis, and axial spondyloarthritis.
d) GB1275
GB1275 is another monoclonal antibody that inhibits the CD73 pathway. This product targets the tumor microenvironment to enhance anti-tumor immune responses and is being explored for a range of cancers.
Services
In addition to its extensive product development pipeline, Gossamer Bio provides several critical services to bolster its research and clinical efforts:
a) Preclinical Testing
The company conducts rigorous preclinical testing using animal models to evaluate the safety and efficacy of its therapeutic candidates before advancing them to human trials.
b) Clinical Trial Design
Gossamer Bio specializes in designing robust clinical trials aimed at reliably assessing the safety, tolerability, and efficacy of its products in human subjects. This includes tailored approaches that fit the specific needs of each therapeutic area.
c) Regulatory Affairs
The company has a dedicated regulatory affairs team that provides comprehensive support for submissions to regulatory bodies to ensure compliance with safety and efficacy standards, facilitating the path to market.
d) Manufacturing
Gossamer Bio collaborates with contract manufacturing organizations (CMOs) to produce clinical trial materials and, ultimately, to support the commercialization of its therapeutic candidates. This partnership model ensures that the products meet the requisite quality and scalability for potential market demand.
In conclusion, Gossamer Bio Inc. positions itself as a dynamic leader in the biopharmaceutical industry through its multifaceted approach to developing cutting-edge therapies across immunology, inflammation, and oncology, supported by a robust suite of services that enhance its research capabilities.
1. Segments
a) Immunology
The Immunology segment of Gossamer Bio aims to create next-generation therapeutics for various autoimmune and allergic conditions. This includes diseases such as:
- Asthma: Gossamer is focused on developing treatments that can potentially provide more effective control of asthma symptoms and prevent exacerbations.
- Inflammatory Bowel Disease (IBD): This encompasses conditions such as Crohns disease and ulcerative colitis, where the company is exploring innovative treatments to improve patient outcomes and quality of life.
- Dermatitis: Gossamers research includes therapies targeted at various forms of dermatitis, potentially alleviating symptoms and addressing underlying mechanisms of these diseases.
- Psoriasis: The company is developing therapies aimed at the root causes of psoriasis, a chronic inflammatory skin condition.
b) Inflammation
This segment is centered on addressing chronic inflammatory diseases, experiencing significant advancements with a focus on:
- Chronic Obstructive Pulmonary Disease (COPD): Gossamer is committed to developing new medications that can reduce inflammation in the lungs and enhance airflow, thereby improving patient conditions.
- Idiopathic Pulmonary Fibrosis (IPF): Gossamer’s research in this area includes finding therapies that can mitigate lung scarring and improve respiratory function.
- Kidney Diseases: The company is exploring innovative approaches to treating various chronic kidney conditions that are driven by inflammatory processes.
c) Oncology
In the Oncology segment, Gossamer Bio is dedicated to innovating therapies for a variety of cancers:
- Hematologic Malignancies: This includes blood cancers such as leukemias and lymphomas, for which Gossamer is targeting distinct pathways to improve treatment outcomes.
- Solid Tumors: The company works on therapies designed to combat solid tumors, which can encompass various forms of cancer affecting organs and tissues throughout the body.
- Rare Cancers: Gossamer is also focusing on therapies for rare cancers, where options are often limited and there exists a critical need for new treatment modalities.
Products
Gossamer Bio’s product portfolio features several promising candidates that are at various stages of development:
a) GB001
GB001 is a selective inhibitor of the prostaglandin D2 receptor 2 (DP2). It is primarily being developed for treating asthma and other allergic diseases, aiming to block inflammatory pathways involved in these conditions.
b) GB002
GB002 is a small molecule inhibitor of the HER3 receptor, which plays a crucial role in cancer cell proliferation. This product is being developed to target various types of cancer, particularly those resistant to other therapies.
c) GB004
GB004 is a monoclonal antibody designed to target the IL-17 pathway, which is integral to many inflammatory diseases. It holds potential for treating conditions like psoriasis, psoriatic arthritis, and axial spondyloarthritis.
d) GB1275
GB1275 is another monoclonal antibody that inhibits the CD73 pathway. This product targets the tumor microenvironment to enhance anti-tumor immune responses and is being explored for a range of cancers.
Services
In addition to its extensive product development pipeline, Gossamer Bio provides several critical services to bolster its research and clinical efforts:
a) Preclinical Testing
The company conducts rigorous preclinical testing using animal models to evaluate the safety and efficacy of its therapeutic candidates before advancing them to human trials.
b) Clinical Trial Design
Gossamer Bio specializes in designing robust clinical trials aimed at reliably assessing the safety, tolerability, and efficacy of its products in human subjects. This includes tailored approaches that fit the specific needs of each therapeutic area.
c) Regulatory Affairs
The company has a dedicated regulatory affairs team that provides comprehensive support for submissions to regulatory bodies to ensure compliance with safety and efficacy standards, facilitating the path to market.
d) Manufacturing
Gossamer Bio collaborates with contract manufacturing organizations (CMOs) to produce clinical trial materials and, ultimately, to support the commercialization of its therapeutic candidates. This partnership model ensures that the products meet the requisite quality and scalability for potential market demand.
In conclusion, Gossamer Bio Inc. positions itself as a dynamic leader in the biopharmaceutical industry through its multifaceted approach to developing cutting-edge therapies across immunology, inflammation, and oncology, supported by a robust suite of services that enhance its research capabilities.